Key Takeaways:
Mauna Kea Technologies reported a 7% rise in 2025 sales and a nearly 70% reduction in debt, signaling a potential financial inflection point for the inventor of the Cellvizio imaging platform after a court-supervised restructuring.
"2025 was perhaps the most transformative year yet for Mauna Kea Technologies and what I believe is an inflection point in our financial and commercial performance," Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies, said in a statement. "We have improved the Company's balance sheet, including reducing our debt by €27M."
The medical device maker posted full-year sales of €8.2 million, up from €7.7 million in 2024, driven by a 38% surge in U.S. sales at constant exchange rates. A non-recurring financial income of €21.3 million from debt write-offs pushed the company to a net profit of €10.8 million for the year, a sharp reversal from a €10.4 million loss in 2024. The growth momentum accelerated into the new year, with first-quarter 2026 core product sales climbing 68 percent.
The successful safeguard procedure and renewed commercial momentum provide a clearer path toward the company's goal of profitability by 2027. With a strengthened balance sheet and growing adoption of its Cellvizio platform, particularly in the U.S., Mauna Kea is now positioned to scale its operations after a period of financial uncertainty.
The company's comprehensive debt restructuring was the primary driver of its return to net profitability. The plan, executed under a French court-supervised safeguard proceeding, resulted in €20.3 million in debt waivers. This reduced total financial debt from approximately €40 million to €12 million, fundamentally resetting the company's balance sheet.
Strict cost discipline also contributed to an improved operating performance. Adjusted EBITDA improved to a loss of €3.0 million from a €4.0 million loss in the prior year, while operating cash burn was reduced by 34 percent. The company ended 2025 with a cash position of €5.0 million, providing financial visibility until early 2027.
The commercial acceleration was led by the United States, which accounted for 80% of total product sales by the fourth quarter of 2025. The growth was supported by increased adoption of the Cellvizio platform for the pancreatic cyst indication. The company's CellTolerance application for food intolerances also emerged as a key growth pillar, surpassing €1 million in global sales.
Momentum continued into the first quarter of 2026, with U.S. sales growing 34% and international sales surging 326% at constant exchange rates. The company also recently secured a European CE Mark under the new Medical Device Regulation (MDR), paving the way for further international expansion in the UK and Switzerland. A strategic partnership with TaeWoong Medical USA is expected to begin generating revenue in the second quarter of 2026.
This article is for informational purposes only and does not constitute investment advice.
